Symbols

RIGL

Rigel Pharmaceuticals·NASDAQ

--(--)

RIGL fundamentals

RIGL Q4 2025 Earnings

Rigel Pharmaceuticals (RIGL) released its earnings on Mar 3, 2026: revenue was 69.80M (YoY +21.19%), beat estimates; EPS was 13.54 (YoY +1592.50%), beat estimates.

Revenue / YoY

69.80M

+21.19%

EPS / YoY

13.54

+1592.50%

Report date

Mar 3, 2026

RIGL Earnings Call Summary for Q4,2025

Revenue Surge: 2025 net product sales hit $232M (+60% YoY), driven by TAVALISSE, GAVRETO, and REZLIDHIA.
R289 Breakthrough: 33% of evaluable MDS patients achieved transfusion independence in Phase Ib study.
Financial Strength: 2025 GAAP net income of $367M, with 2026 guidance for $275-290M revenue and positive net income.
Strategic Expansion: Pursuing late-stage in-licensing deals and advancing R289 toward potential registration.

Earnings

EPS

Revenue

Revenue & Expenses

RIGL has released its 2025 Q4 earnings report, with revenue of 69.80M, reflecting a YoY change of 21.19%, and net profit of 268.06M, showing a YoY change of 1769.22%. The Sankey diagram below clearly presents RIGL's revenue sources and cost distribution.

Key Indicators

Rigel Pharmaceuticals (RIGL) key financial stats and ratios, covering profitability, financial health, and leverage.

Income Statement

Rigel Pharmaceuticals (RIGL)'s revenue and profit trends over recent years, visualized with a waterfall chart to showcase the revenue-to-profit funnel.

Trend

Breakdown

Balance Sheet

Rigel Pharmaceuticals (RIGL)'s asset and liability trends over recent years, visualized with a waterfall chart to illustrate changes in its asset-liability structure.

Trend

Breakdown

Cash Flow

Rigel Pharmaceuticals (RIGL)'s cash flow trends over recent years, visualized with a waterfall chart to illustrate changes in its operating, investing, and financing cash flows.

Trend

Breakdown